Key result
Heparin neutralizes the inhibitory effect of prostacyclin (PGI2) on platelet aggregation and cyclic AMP levels without losing its own anticoagulant activity.
Answers are grounded in this paper and cite their sources.
May alter platelet inhibition in heparin-treated patients; leaves open clinical relevance and requires prospective validation.
Heparin neutralizes the inhibitory effect of prostacyclin (PGI2) on platelet aggregation. The PGI2-induced enhancement of platelet cyclic adenosine monophosphate levels is also inhibited. The mechanism appears to involve a direct interaction in which heparin neutralizes the inhibitory effects of PGI2 on platelet aggregation but, at the same time, does not lose its own anticoagulant activity. These findings may explain instances in which heparin infusions have been reported to produce hyperaggregation of platelets, thrombotic episodes, and thrombocytopenia in patients.
No takes yet. Share an insight, caveat, or question.
Saba et al. (1979) studied this question. Heparin was evaluated on Platelet aggregation and cyclic adenosine monophosphate levels. Heparin neutralizes the inhibitory effect of prostacyclin (PGI2) on platelet aggregation and cyclic AMP levels without losing its own anticoagulant activity.
Synapse has enriched 10 related papers. Consider them for comparative context: